Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Last trade$72.70
Day change-$0.095 (-0.13%)
Day range$72.64 – $72.82
Volume3,557,675
Market cap$11.43B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$11.43B
Price / earnings
66.49×
Price / book
5.28×
Price / sales
9.31×
EV / sales
9.19×
EV / EBITDA
33.43×
Profitability
Earnings per share
$1.09
Return on assets
6.52%
Return on equity
7.94%
Dividend yield
0.44%
Liquidity and leverage
Debt / equity
0.09×
Current ratio
2.28×
Quick ratio
1.74×
Cash ratio
0.97×
Cash flow
Price / cash flow
33.87×
Price / free cash flow
37.1×
Free cash flow
$308.2M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TECH, quarterly periods
Line item
Q1 FY2027 Sep 30, 2026
Q4 FY2026 Jun 30, 2026
Q3 FY2026 Mar 31, 2026
Q2 FY2026 Dec 31, 2025
Q1 FY2026 Sep 30, 2025
Q4 FY2025 Jun 30, 2025
Q3 FY2025 Mar 31, 2025
Q2 FY2025 Dec 31, 2024
Revenue
$299.71M
$321.19M
$311.42M
$295.88M
$286.56M
$316.96M
$316.18M
$297.03M
Cost of revenue
$103.09M
$109.8M
$103.13M
$104.6M
$98.44M
$118.15M
$101.63M
$103.15M
Gross profit
$196.62M
$211.39M
$208.29M
$191.28M
$188.11M
$198.81M
$214.56M
$193.89M
Selling, general and administrative
$133.68M
$113.17M
$109.34M
$113.69M
$116.21M
$196.64M
$151.27M
$121.45M
Research and development
$26.34M
$23.95M
$23.46M
$23.13M
$24.24M
$26.03M
$24.58M
$25.02M
Total operating expenses
$160.02M
$137.12M
$132.79M
$136.82M
$140.45M
$222.67M
$175.85M
$146.47M
Operating income
$36.6M
$74.28M
$75.5M
$54.46M
$47.66M
-$23.86M
$38.71M
$47.42M
Interest expense
$0
-$9.63M
$0
$0
$0
-$8.51M
$0
$0
Income before taxes
$34.69M
$70.68M
$71.23M
$50.78M
$47.99M
-$22.86M
$38.27M
$42.88M
Income taxes
$6.4M
$16.06M
$20.18M
$12.78M
$9.81M
-$5.18M
$15.69M
$7.99M
Net income
$28.29M
$54.62M
$51.05M
$38.01M
$38.19M
-$17.68M
$22.59M
$34.89M
Net income attributable to common shareholders
$28.29M
$54.62M
$51.05M
$38.01M
$38.19M
-$17.68M
$22.59M
$34.89M
EBITDA
$60.33M
$98.42M
$99.66M
$79.17M
$72M
$3.25M
$66.28M
$74.5M
Basic earnings per share
$0.18
$0.35
$0.33
$0.24
$0.25
-$0.11
$0.14
$0.22
Diluted earnings per share
$0.18
$0.35
$0.32
$0.24
$0.24
-$0.11
$0.14
$0.22
Recent news
Company coverage with links to the original publishers.
CorMedix (CRMD) reported a quarterly loss of $0.04 per share, beating consensus estimates of $0.09 loss by 55.56%, but revenues declined to $54.52 million from $104.28 million year-over-year. The stock has underperformed the market by 54.4% this year and carries a Zacks Rank #3 (Hold) rating. Techne (TECH), a peer in the medical testing industry, is expected to report earnings of $0.46 per share with modest revenue growth of 2.4%.
Humacyte, Inc. (HUMA) reported a quarterly loss of $0.07 per share, beating consensus estimates of $0.09 loss, with a 22.22% earnings surprise. Revenue reached $1.03 million, surpassing estimates by 19.54%. However, the stock has declined 52.6% year-to-date versus the S&P 500's 10.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Bio-Techne (TECH) reported Q1 FY2027 adjusted EPS of 44 cents, up 4.8% YoY and beating estimates by 10%, with revenues growing 5% to $299.7M. Protein Sciences segment revenues rose 9% to $219.7M, while Diagnostics and Spatial Biology grew modestly at 1%. Shareholders approved the merger with Merck KGaA valued at $11.3 billion ($73/share), expected to close by late 2026 or early 2027.
Roivant Sciences (ROIV) reported a quarterly loss of $0.19 per share, beating consensus estimates of $0.41 loss by 53.66%. The company's revenues reached $35.12 million, significantly surpassing estimates. Despite strong year-to-date performance of 79.2% versus the S&P 500's 7.8%, the stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Rhythm Pharmaceuticals reported a Q3 loss of $0.61 per share, beating consensus estimates of $0.68 loss, with a 10.29% earnings surprise. Revenue reached $92.13 million, surpassing estimates by 9.07% and nearly doubling year-ago revenues of $51.3 million. However, the stock has underperformed the market, down 12.7% year-to-date versus the S&P 500's 10.2% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Nov 13, 2026
$0.08
Nov 23, 2026
recurring
Aug 24, 2026
$0.08
Sep 4, 2026
recurring
May 18, 2026
$0.08
May 29, 2026
recurring
Feb 13, 2026
$0.08
Feb 27, 2026
recurring
Nov 17, 2025
$0.08
Nov 28, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.